Roche's Divarasib Beats Rivals in Lung Cancer Trial
The drug achieved a median overall survival of 17.7 months compared to 12.0 months for competitors sotorasib and adagrasib.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
2 publishers have covered this in 3 articles since 26 Oct 2026. Quartz published first, on 26 October at 12:20 UTC; STAT followed 10h 57m later. The most recent article, from STAT, appeared on 26 October at 23:17 UTC.
Outlets reporting it: Quartz, STAT.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Roche
- divarasib
- sotorasib
- adagrasib